Pages that link to "Q114400579"
Jump to navigation
Jump to search
The following pages link to Edward K Geissler (Q114400579):
Displaying 50 items.
- Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort (Q26773299) (← links)
- Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies (Q28596281) (← links)
- DHRS9 is a Stable Marker of Human Regulatory Macrophages (Q30491942) (← links)
- Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice (Q33361843) (← links)
- A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma (Q33575450) (← links)
- Study Protocol: A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function. PATRON-Study (Q33692413) (← links)
- DX5+NKT cells display phenotypical and functional differences between spleen and liver as well as NK1.1-Balb/c and NK1.1+ C57Bl/6 mice (Q33884869) (← links)
- Single cell tracking of gadolinium labeled CD4+ T cells by laser ablation inductively coupled plasma mass spectrometry (Q35002558) (← links)
- In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies (Q35184210) (← links)
- Laser ablation-inductively coupled plasma mass spectrometry: an emerging technology for detecting rare cells in tissue sections (Q35212145) (← links)
- Laser Ablation Inductively Coupled Plasma Mass Spectrometry: An Emerging Technology for Multiparametric Analysis of Tissue Antigens (Q36097268) (← links)
- Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. (Q36381360) (← links)
- Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation (Q36527033) (← links)
- Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs (Q36578322) (← links)
- IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients (Q36673682) (← links)
- Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin (Q37028215) (← links)
- Extended pancreas donor program - the EXPAND study rationale and study protocol (Q37028375) (← links)
- Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression (Q37052844) (← links)
- Mesenchymal stem cells can affect solid organ allograft survival (Q37474205) (← links)
- Procedures for ethical review for clinical trials within the EU. (Q37493991) (← links)
- Mesenchymal stem cells as immunomodulators after liver transplantation (Q37605679) (← links)
- ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) does not affect proliferation, apoptosis, or angiogenesis as compared to standard liver resection for colorectal liver metastases (Q37686394) (← links)
- The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation (Q37791408) (← links)
- Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence (Q37856169) (← links)
- Human regulatory macrophages as a cell-based medicinal product. (Q37970215) (← links)
- Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. (Q38025841) (← links)
- Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients (Q38120393) (← links)
- Clinical management of patients receiving cell-based immunoregulatory therapy. (Q38201742) (← links)
- Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). (Q38292656) (← links)
- Now or never? The case for cell-based immunosuppression in kidney transplantation. (Q38367524) (← links)
- Evidence-based medicine in daily surgical decision making: a survey-based comparison between the UK and Germany (Q38394409) (← links)
- Hurdles in therapy with regulatory T cells (Q38583881) (← links)
- Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment (Q39197674) (← links)
- Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. (Q39321109) (← links)
- MITAP-compliant characterization of human regulatory macrophages (Q39329676) (← links)
- Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors (Q39404561) (← links)
- Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. (Q39480718) (← links)
- Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells (Q39746076) (← links)
- Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice (Q39904702) (← links)
- Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes (Q39918833) (← links)
- Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo (Q40048188) (← links)
- Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or (Q40058972) (← links)
- Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo (Q40158485) (← links)
- Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability (Q40160158) (← links)
- Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model (Q40182123) (← links)
- Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. (Q40478257) (← links)
- Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma (Q41081521) (← links)
- Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models (Q41781449) (← links)
- First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation (Q41950774) (← links)
- Improved Outcome after ‘Bottom-Up’ Immunosuppression in Liver Transplant Recipients with Preoperative Renal Impairment (Q42800559) (← links)